EUVIMEDOpdag EUVIMED
Crossref

5‐Heptadecylresorcinol ameliorates high‐fat diet induced non‐alcoholic fatty liver disease through modulating bile acid profile and suppressing inflammation

Zihui Yang, Yiming Hao, Ziyuan Wang iD, Zongwei Wang, Gaoqi Ye, Fei Gao, Jing Wang iD, Jie Liu iD

Journal of the Science of Food and Agriculture · 2025

DOI: 10.1002/jsfa.70060 ↗

At a glance

Journal article in Journal of the Science of Food and Agriculture, 2025. Written by Zihui Yang and 7 co-authors. Institution: Key Laboratory of Geriatric Nutrition and Health (Beijing Technology and Business University), Ministry of Education, Beijing, China. Major MEDLINE topics: Non-alcoholic Fatty Liver Disease, Resorcinols, Bile Acids and Salts. Cited 1 times so far (Crossref); 46 references. Funded by: National Natural Science Foundation of China (32172207), Beijing Nova Program (20230484307), Project of Cultivation for young topnotch Talents of Beijing Municipal Institutions (BPHR202203041).

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

BACKGROUND The risk of non‐alcoholic fatty liver disease (NAFLD) has been inversely associated with whole grain consumption. 5‐Heptadecylresorcinol (AR‐C17) is a phenolic lipid present in the bran part of whole grain wheat, which has been proven to ameliorate obesity and atherosclerosis. However, whether AR‐C17 could alleviate NAFLD and the underlying molecular mechanisms remain unclear. RESULTS AR‐C17 administration (150 mg/kg) significantly attenuated high‐fat diet (HFD)‐induced NAFLD in mice by reducing serum total cholesterol (TC), low‐density lipoprotein cholesterol (LDL‐C), and aspartate aminotransferase (AST) levels, accompanied by significant improvements in hepatic steatosis, inflammation, and fibrosis. Accordingly, serum metabolomics revealed distinct clustering of different treatment groups, and the pathway enrichment analyses indicated that AR‐C17 could significantly modulate primary bile acid biosynthesis. Hepatic target metabolomics further confirmed that AR‐C17 administration profoundly altered bile acid profiles. Western‐blot analysis showed that AR‐C17 treatment up‐regulated FXR (farnesoid X receptor) expression and inhibited the activation of NLRP3 (nucleotide‐binding oligomerization domain‐like receptor with a pyrin domain 3) inflammasome. CONCLUSION AR‐C17 mitigated the progression of NAFLD by modulating the hepatic bile acid profile and reducing systemic inflammation through FXR signaling pathway. © 2025 Society of Chemical Industry.

Subjects

MeSH terms (MEDLINE)

Non-alcoholic Fatty Liver DiseaseResorcinolsBile Acids and SaltsAnimalsDiet, High-FatMaleMiceMice, Inbred C57BLLiverReceptors, Cytoplasmic and NuclearHumansNLR Family, Pyrin Domain-Containing 3 ProteinAspartate AminotransferasesTriticumReceptor, Farnesoid X-Activated

Author keywords

5‐heptadecylresorcinolFXRNAFLDbile acidinflammation

Substances

ResorcinolsBile Acids and SaltsReceptors, Cytoplasmic and NuclearNLR Family, Pyrin Domain-Containing 3 ProteinAspartate AminotransferasesReceptor, Farnesoid X-Activated

Authors and institutions

  • Key Laboratory of Geriatric Nutrition and Health (Beijing Technology and Business University), Ministry of Education, Beijing, China.
  • Aviation Health Assurance and Flight Safety Research Laboratory, Air Force Medical Center, Air Force Medical University, Beijing, China.
  • National Center of Technology Innovation for Grain Industry (Comprehensive Utilization of Edible By-products), Beijing Technology and Business University, Beijing, China.

ORCID profiles: Ziyuan Wang, Jing Wang, Jie Liu

Funding

  • National Natural Science Foundation of China (32172207)
  • Beijing Nova Program (20230484307)
  • Project of Cultivation for young topnotch Talents of Beijing Municipal Institutions (BPHR202203041)
  • Youth Talent Program of National Food and Strategic Reserves (QN2024403)

Cite

APA

Yang, Z., Hao, Y., Wang, Z., Wang, Z., Ye, G., Gao, F., Wang, J., & Liu, J. (2025). 5‐Heptadecylresorcinol ameliorates high‐fat diet induced non‐alcoholic fatty liver disease through modulating bile acid profile and suppressing inflammation. Journal of the Science of Food and Agriculture. https://doi.org/10.1002/jsfa.70060

Vancouver

Yang Z, Hao Y, Wang Z, Wang Z, Ye G, Gao F, et al. 5‐Heptadecylresorcinol ameliorates high‐fat diet induced non‐alcoholic fatty liver disease through modulating bile acid profile and suppressing inflammation. Journal of the Science of Food and Agriculture. 2025. doi:10.1002/jsfa.70060

BibTeX
@article{Yang2025,
  author = {Yang, Zihui and Hao, Yiming and Wang, Ziyuan and Wang, Zongwei and Ye, Gaoqi and Gao, Fei and Wang, Jing and Liu, Jie},
  title = {5‐Heptadecylresorcinol ameliorates high‐fat diet induced non‐alcoholic fatty liver disease through modulating bile acid profile and suppressing inflammation},
  journal = {Journal of the Science of Food and Agriculture},
  year = {2025},
  doi = {10.1002/jsfa.70060}
}
Start for free →